Inflammatory responses to influenza vaccination at the extremes of age

Immunology

Volumn 151, Issue 4, 2017, Pages 451-463

  McDonald, Jacqueline U ^a   Zhong, Ziyun ^a   Groves, Helen T ^a   Tregoning, John S ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

cytokine; lung; mucosa; vaccination; viral

Indexed keywords

C REACTIVE PROTEIN; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLUENZA VACCINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 2; MIFAMURTIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR; VASCULOTROPIN; VIRUS RNA; AUTACOID; CYTOKINE; MF59 OIL EMULSION; POLYSORBATE; SQUALENE; VIRUS ANTIBODY;

ADULT; AGE; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CYTOKINE RESPONSE; DRUG EFFICACY; IMMUNE RESPONSE; INFECTION; INFLAMMATION; INFLUENZA A (H1N1); INFLUENZA VACCINATION; MOUSE; NEWBORN; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; VIRUS LOAD; YOUNG ADULT; AGING; ANIMAL; BLOOD; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H1N1); LUNG; METABOLISM; ORTHOMYXOVIRUS INFECTION; VACCINATION; VIROLOGY;

AGING; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, VIRAL; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LUNG; MICE; ORTHOMYXOVIRIDAE INFECTIONS; POLYSORBATES; SQUALENE; VACCINATION;

EID: 85019228629     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12742     Document Type: Article

References (45)

1. Preaud E, Durand L, Macabeo B, Farkas N, Sloesen B, Palache A et al. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. BMC Public Health 2014; 14:813.
2. Lafond KE, Nair H, Rasooly MH, Valente F, Booy R, Rahman M et al. Global role and burden of influenza in pediatric respiratory hospitalizations, 1982–2012: a systematic analysis. PLoS Med 2016; 13:e1001977.
3. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng P-Y, Steiner C et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993–2008. Clin Infect Dis 2012; 54:1427–36.
4. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009; 9:185–94.
5. Monto AS, Ohmit SE. Seasonal influenza vaccines: evolutions and future trends. Expert Rev Vaccines 2009; 8:383–9.
6. Principi N, Esposito S, Marchisio P. Present and future of influenza prevention in pediatrics. Expert Opin Biol Ther 2011; 11:641–53.
7. Amanna IJ. Balancing the efficacy and safety of vaccines in the elderly. Open Longev Sci 2012; 6:64–72.
8. Tregoning JS, Yamaguchi Y, Harker J, Wang B, Openshaw PJ. The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice. J Virol 2008; 82:4115–24.
9. Siggins MK, Gill SK, Langford PR, Li Y, Ladhani SN, Tregoning JS. PHiD-CV induces anti-Protein D antibodies but does not augment pulmonary clearance of nontypeable Haemophilus influenzae in mice. Vaccine 2015; 33:4954–61.
10. + T cell responses, enabling faster resolution of influenza disease. Front Immunol 2016; 7:321. doi: 10.3389/fimmu.2016.00321.
11. Russell RF, McDonald JU, Lambert L, Tregoning JS. Use of the microparticle nanoscale silicon dioxide as an adjuvant to boost vaccine immune responses against influenza virus in neonatal mice. J Virol 2016; 90:4735–44.
12. McDonald JU, Ekeruche-Makinde J, Ho MM, Tregoning JS, Ashiru O. Development of a custom pentaplex sandwich immunoassay using Protein-G coupled beads for the Luminex® xMAP® platform. J Immunol Methods 2016; 433:6–16.
13. Team R Development Core team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R foundation for statistical computing, 2011.
14. Tang YHM, Li W. ggfortify: Unified Interface to Visualize Statistical Result of Popular R Packages. The R Journal 2016.
15. Ligges UMM. Scatterplot3d – an R Package for visualizing multivariate data. J Stat Softw 2003; 8:1–20.
16. Pavlidis P, Noble WS. Matrix2png: a utility for visualizing matrix data. Bioinformatics 2003; 19:295–6.
17. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007; 7:379–90.
18. Kollmann TR, Marchant A. Towards predicting protective vaccine responses in the very young. Trends Immunol 2016; 37:523–34.
19. Russell RF, McDonald JU, Lambert L, Tregoning JS. Use of the microparticle NanoSiO2 as an adjuvant to boost vaccine immune responses in neonatal mice against influenza. J Virol 2016; 90:4735–44.
20. Khalil SM, Tonkin DR, Snead AT, Parks GD, Johnston RE, White LJ. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice. J Virol 2014; 88:9182–96.
21. Sherman MP, Pritzl CJ, Xia C, Miller MM, Zaghouani H, Hahm B. Lactoferrin acts as an adjuvant during influenza vaccination of neonatal mice. Biochem Biophys Res Commun 2015; 467:766–70.
22. Mastelic GB, Eberhardt CS, Auderset F, Castellino F, Seubert A, Tregoning JS et al. MF59 mediates its B cell adjuvanticity by promoting T follicular helper cells and thus germinal center responses in adult and early life. J Immunol 2015; 194:4836–45.
23. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007; 128:92–105.
24. Puchta A, Naidoo A, Verschoor CP, Loukov D, Thevaranjan N, Mandur TS et al. TNF drives monocyte dysfunction with age and results in impaired anti-pneumococcal immunity. PLoS Pathog 2016; 12:e1005368.
25. Yam KK, Gupta J, Allen EK, Burt KR, Beaulieu É, Mallett CP et al. Comparison of AS03 and alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice. Vaccine 2016; 34:1444–51.
26. Bernstein ED, Gardner EM, Abrutyn E, Gross P, Murasko DM. Cytokine production after influenza vaccination in a healthy elderly population. Vaccine 1998; 16:1722–31.
27. Higgins DA, Carlson JR, Van Nest G. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 1996; 14:478–84.
28. Toapanta FR, Ross TM. Impaired immune responses in the lungs of aged mice following influenza infection. Respir Res 2009; 10:1–19.
29. Ramirez A, Co M, Mathew A. CpG improves influenza vaccine efficacy in young adult but not aged mice. PLoS ONE 2016; 11:e0150425.
30. Leng J, Stout-Delgado HW, Kavita U, Jacobs A, Tang J, Du W et al. Efficacy of a vaccine that links viral epitopes to flagellin in protecting aged mice from influenza viral infection. Vaccine 2011; 29:8147–55.
31. Aspinall R, Henson SM, Pido-Lopez J. My T's gone cold. I'm wondering why. Nat Immunol 2003; 4:203–5.
32. Gasparini R, Pozzi T, Montomoli E, Fragapane E, Senatore F, Minutello M et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001; 17:135–40.
33. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 2009; 4:e4384.
34. Fragapane E, Gasparini R, Schioppa F, Laghi-Pasini F, Montomoli E, Banzhoff A. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin Vaccine Immunol 2010; 17:1817–19.
35. Scheifele DW, McNeil SA, Ward BJ, Dionne M, Cooper C, Coleman B et al. Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison. Hum Vaccin Immunother 2013; 9:2460–73.
36. Reber AJ, Kim JH, Biber R, Talbot HK, Coleman LA, Chirkova T et al. Preexisting immunity, more than aging, influences influenza vaccine responses. Open Forum Infect Dis 2015; 2:ofv052–ofv.
37. Lang P-O, Mendes A, Socquet J, Assir N, Govind S, Aspinall R. Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence. Clin Interv Aging 2012; 7:55–64.
38. Nakaya HI, Clutterbuck E, Kazmin D, Wang L, Cortese M, Bosinger SE et al. Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. Proc Natl Acad Sci USA 2016; 113:1853–8.
39. Frey SE, Reyes MR, Reynales H, Bermal NN, Nicolay U, Narasimhan V et al. Comparison of the safety and immunogenicity of an MF59(R)-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 2014; 32:5027–34.
40. Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 2008; 105:10501–6.
41. Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O'Hagan DT et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011; 29:1812–23.
42. Cantisani R, Pezzicoli A, Cioncada R, Malzone C, De Gregorio E, D'Oro U et al. Vaccine adjuvant MF59 promotes retention of unprocessed antigen in lymph node macrophage compartments and follicular dendritic cells. J Immunol 2015; 194:1717–25.
43. Calabro S, Tritto E, Pezzotti A, Taccone M, Muzzi A, Bertholet S et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 2013; 31:3363–9.
44. Knudsen NP, Olsen A, Buonsanti C, Follmann F, Zhang Y, Coler RN et al. Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. Sci Rep 2016; 6:19570.
45. Lewis DJ, Lythgoe MP. Application of “Systems vaccinology” to evaluate inflammation and reactogenicity of adjuvanted preventative vaccines. J Immunol Res 2015; 2015:909406.